Pregnancy after breast cancer in BRCA1/2 mutation carriers

Jeļena Maksimenko; Arvīds Irmejs; Jānis Gardovskis

doi:10.1186/s13053-022-00209-1

Pregnancy after breast cancer in BRCA1/2 mutation carriers

Jeļena Maksimenko (Corresponding Author)
, Arvīds Irmejs
, Jānis Gardovskis

Department of Surgery

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

7 Downloads (Pure)

Abstract

Background: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers. Methods: A broad review of the literature was conducted using MEDLINE (via PubMed) for relevant articles published. Main body of the abstract: This review summarizes the impact of different cytotoxic agents on a fertility, fertility preservation, maternal and fetal prognosis after pregnancy in breast cancer survivors with BRCA1/2. Conclusion: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients’ needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment.

Original language	English
Article number	3
Pages (from-to)	3
Number of pages	7
Journal	Hereditary Cancer in Clinical Practice
Volume	20
Issue number	1
DOIs	https://doi.org/10.1186/s13053-022-00209-1 https://doi.org/10.1186/s13053-022-00209-1
Publication status	Published - 21 Jan 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

Pregnancy after breast cancer inFinal published version, 592 KBLicence: CC BY

Cite this

@article{dce8215cfe2c48388f5d7ee94b82e185,

title = "Pregnancy after breast cancer in BRCA1/2 mutation carriers",

abstract = "Background: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers. Methods: A broad review of the literature was conducted using MEDLINE (via PubMed) for relevant articles published. Main body of the abstract: This review summarizes the impact of different cytotoxic agents on a fertility, fertility preservation, maternal and fetal prognosis after pregnancy in breast cancer survivors with BRCA1/2. Conclusion: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients{\textquoteright} needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment.",

author = "Jeļena Maksimenko and Arvīds Irmejs and Jānis Gardovskis",

note = "Funding Information: This research is supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)?Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme ?ERN-2016?Framework Partnership Agreement 2017?2021. Funding Information: This research is supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)—Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme “ERN-2016—Framework Partnership Agreement 2017–2021. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jan,

day = "21",

doi = "10.1186/s13053-022-00209-1",

language = "English",

volume = "20",

pages = "3",

journal = "Hereditary Cancer in Clinical Practice",

issn = "1731-2302",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Pregnancy after breast cancer in BRCA1/2 mutation carriers

AU - Maksimenko, Jeļena

AU - Irmejs, Arvīds

AU - Gardovskis, Jānis

N1 - Funding Information: This research is supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)?Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme ?ERN-2016?Framework Partnership Agreement 2017?2021. Funding Information: This research is supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)—Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme “ERN-2016—Framework Partnership Agreement 2017–2021. Publisher Copyright: © 2022, The Author(s).

PY - 2022/1/21

Y1 - 2022/1/21

N2 - Background: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers. Methods: A broad review of the literature was conducted using MEDLINE (via PubMed) for relevant articles published. Main body of the abstract: This review summarizes the impact of different cytotoxic agents on a fertility, fertility preservation, maternal and fetal prognosis after pregnancy in breast cancer survivors with BRCA1/2. Conclusion: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients’ needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment.

AB - Background: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers. Methods: A broad review of the literature was conducted using MEDLINE (via PubMed) for relevant articles published. Main body of the abstract: This review summarizes the impact of different cytotoxic agents on a fertility, fertility preservation, maternal and fetal prognosis after pregnancy in breast cancer survivors with BRCA1/2. Conclusion: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients’ needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment.

UR - https://www.scopus.com/pages/publications/85123345262

U2 - 10.1186/s13053-022-00209-1

DO - 10.1186/s13053-022-00209-1

M3 - Review article

C2 - 35062994

SN - 1731-2302

VL - 20

SP - 3

JO - Hereditary Cancer in Clinical Practice

JF - Hereditary Cancer in Clinical Practice

IS - 1

M1 - 3

ER -

Pregnancy after breast cancer in BRCA1/2 mutation carriers

Abstract

UN SDGs

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this